Network Meta-analysis of Food and Drug Administration-approved Treatment Options for Adults with Aquaporin-4 Immunoglobulin G-positive Neuromyelitis Optica Spectrum Disorder.
Dean M WingerchukIna ZhangAdrian KielhornMinying RoystonMichael LevyKazuo FujiharaIchiro NakashimaImran TanvirFriedemann PaulSean J PittockPublished in: Neurology and therapy (2021)
The NMA results suggest that complement component 5 (C5) inhibition prevents NMOSD relapses more effectively than broader mechanisms of action.